|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Hematology,Nephrology,and Rheumatology |
IKEDA Sho
|
|
|
Graduating School 【 display / non-display 】
-
2003.04-2009.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
2012.04-2016.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2022.04-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Hematology,Nephrology,and Rheumatology Lecturer
-
2019.04-2022.03
Akita University Hospital Internal MedicineⅢ Assistant Professor
Research Achievements 【 display / non-display 】
-
Matsuda Y, Ikeda S
Cancer Science ( Cancer Science ) 113 ( 4 ) 1208 - 1219 2022 [Refereed]
Research paper (journal) Domestic Co-author
-
Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma
Ikeda S.
Cancer Science ( Cancer Science ) 112 ( 10 ) 3995 - 4004 2021 [Refereed]
Research paper (journal)
-
Ikeda S.
Cancer Science ( Cancer Science ) 111 ( 11 ) 4088 - 4101 2020.11 [Refereed]
Research paper (journal)
-
Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.
Ikeda S, Kobayashi T, Saito M, Komatsuda A, Ubukawa K, Kameoka Y, Takahashi N.
Internal Medicine 58 ( 23 ) 3461 - 3468 2019.12 [Refereed]
Research paper (journal) Domestic Co-author
-
Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.
Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K.
European journal of nuclear medicine and molecular imaging 46 ( 6 ) 1345 - 1350 2019.01 [Refereed]
Research paper (journal) Domestic Co-author
-
Identification of hypoxia-specific therapeutic targets in multiple myeloma
IKEDA Sho
Rinsho Ketsueki ( The Japanese Society of Hematology ) 62 ( 4 ) 305 - 313 2021
<p>The bone marrow microenvironment is low in oxygen, promoting a hypoxic response which causes myeloma cells to acquire stem cell properties and enhanced therapy resistance. We performed comprehensive gene and microRNA expression analyses of samples from myeloma patients and cell lines cultured under hypoxia. Through this, we identified the histone demethylase KDM3A, the glycolytic enzyme HK2, and microRNA-210 as factors playing important roles in the behavior of cells under hypoxic conditions. These genes were regulated by the hypoxia-inducible factor HIF. However, we also found that the expression of IRF4 and MYC, factors required for maintenance of differentiation and proliferation was suppressed by hypoxia. This suggests that the regulatory factors that induce drug resistance and the anti-apoptotic capacity of myeloma cells fluctuate with the partial pressure of oxygen in their environment. Based on this premise, a dual treatment strategy in which a dominant clone and a dormant clone adapted to the hypoxic microenvironment are treated simultaneously with orthogonal drugs is a potentially viable strategy to achieve a cure for multiple myeloma.</p>
-
IKEDA Sho, TAGAWA Hiroyuki
International Journal of Myeloma ( Japanese Society of Myeloma ) 10 ( 1 ) 13 - 19 2020
<p>Multiple myeloma (MM) is a refractory hematological malignant neoplasm derived from plasma cells. It has been extensively studied in the quest to develop treatment strategies. Furthermore, several factors of the bone marrow microenvironment could be candidates for novel therapeutic targets. Among these, the hypoxic response is the most important factor maintaining cell homeostasis, and is generally considered as a therapeutic target for various cancers including MM. Although oxygen partial pressure of bone marrow is 50–55 mmHg, that of hypoxic niche is less than 10 mmHg. Myeloma cells adapting to the hypoxic niche exhibit changes in gene expression via activation of hypoxia-inducible factor (HIF), and subsequently acquiring treatment resistance. However, because of its negative effects on normal cells and tissues, HIF inhibitor is not used in medical practice. Hence, downstream targets of HIF should be investigated. In particular, changes induced by the hypoxic response, such as metabolic pathways, cell dissemination, and malignant bone marrow environment, may be promising therapeutic targets. Therefore, future studies should focus on identifying therapeutic drugs targeting hypoxic environments and hypoxia-inducible genes.</p>
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Young Scientists(B)
Project Year： 2017.04 - 2019.03
Presentations 【 display / non-display 】
-
Myeloma: Biology and Pathophysiology, excluding Therapy
Sho Ikeda, Fumito Abe, Akihiro Kitadate, Yuka Matsuda, Naoto Takahashi, Hiroyuki Tagawa
米国血液学会 2019.12 - 2019.12